Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer
Irreversible pyrimidine-based EGFR inhibitors, including WZ4002, selectively inhibit both EGFR-activating and EGFR inhibitor-resistant T790M mutations more potently than wild-type EGFR. Although this class of mutant-selective EGFR inhibitors is effective clinically in lung cancer patients harboring...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2015
|
| 在線閱讀: | https://doi.org/10.1158/2159-8290.cd-15-0063 https://cancerdiscovery.aacrjournals.org/content/candisc/5/9/960.full.pdf |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|